Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre | BMC Cancer | Full Text

Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre | BMC Cancer | Full Text

Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre

Study aimed to characterise treatment and outcomes for patients with hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC) within a large regional can...

Authors:Chris Twelves, Sue Cheeseman, Will Sopwith, Matthew Thompson, Majid Riaz, Necibe Ahat-Donker, Melissa Myland, Adam Lee, Raymond Przybysz, Stuart Turner, Geoff Hall and Tim Perren

Citation:BMC Cancer 2020 20:53

Content type:Research article

Published on: 21 January 2020

• ViewFull Text
 
• ViewPDF